SBWire

Research's latest report "Contract Research Organization Market: Global Deals and Operational Strategies" discusses the deal making activity during the past five years and in-depth analysis of the key deals involving more than 40 public and privately held CROs. The operational strategies adopted by key players in the recent years have been listed. A heatmap analysis of the key companies was done based on their firm utilization and capital management. SWOT analysis and profiles are given for the key companies in the market.

Research, the leading business intelligence provider, has released its latest research, ""Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs"", which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

Research, the leading business intelligence provider, has released its latest research, ""Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by Research's team of industry experts.

The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. GBI Research's analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products, acting on 13 first-in-class targets. This exceptional first-in-class innovation is largely due to the high number of first-in-class products solely targeting the dystrophin gene, which is the primary genetic cause of DMD and BMD. The strong presence of first-in-class products in the pipeline therefore creates a distinctly different landscape to the market landscape, which relies on symptomatic treatment glucocorticoids. Although Translarna (ataluren) is developed to correct the genetic defects, significant unmet needs remain in the market, as the treatment is applicable to only 10–15% of all DMD cases caused by nonsense mutations.

Research's report, "Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 – Asia-Pacific" provides quantitative analysis of the four multiparameter patient monitoring devices market segments: high acuity monitors, mid acuity monitors, low acuity monitors and multiparameter central stations. The analysis includes market size data by revenue and volume over the 2006-2020 period for the following countries: Australia, Japan, China and India. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Research's report, "Market Digest: Ultrasound Systems Market 2006 to 2020 – Americas" provides quantitative analysis of the two ultrasound systems market segments: stand-alone systems and portable systems. The analysis includes market size data by revenue and volume over the 2006-2020 period for the following countries: US, Brazil and Canada. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research's team of industry experts.

Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.

Research's latest report: "Pharmaceutical Deal Trends (2010–2015) and In-Depth Analysis of Recent Deal Activity" discusses deal-making trends for a range of deal types, such as Mergers & Acquisitions (M&A) and strategic alliances. It also examines preference by deal type, along with disclosed deal values from 2010 to July 2015, covering start-ups, mid-level players, and big players.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8–1% of all cancer cases worldwide and approximately 10% of all hematological cancers, with incidence rates ranging from 0.4 to 5 per 100,000 persons in different parts of the world.

Brandon and Jacque are the both Sales Representatives for The Avanti Company and they will be promoting and showcasing McCrometer's Full Profile Insertion mag meter, inline UltraMag and strap-on McMag. Products will also include the Q700 and EvoQ4 from Elster, Nicor meter lids and the new Do Mac Guardian meter box inflow cap.

Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature.

Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations.

Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for diagnosed patients can be delayed, an option not commonly recommended for aggressive disease. Across both indolent and aggressive disease, first-line chemotherapy in combination with the blockbuster drug rituxumab can induce high rates of response, and prolonged durations of remission. Despite this, indolent disease is typically incurable, with the most aggressive lymphoma subtype - diffuse large B-cell lymphoma having 5-year survival rates of ~50%. Re-treatment with chemotherapy can induce second and subsequent remissions, but most NHL patients develop chemotherapy resistant disease, for whom there are limited treatment options. Overall, in terms of numbers small molecule chemotherapeutic agents dominate the current market, with a clear need for novel targeted therapies to prolong durations of remission, and provide options for patients with chemo resistant, heavily pretreated disease.

The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages.

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%.

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.

Provides understanding and access to the non-hodgkin lymphoma partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The Global Soft Intraocular Lens Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Soft Intraocular Lens industry. In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The 'Global and Chinese Hydraulic Clutch Industry, 2016 Market Research Report' is a professional and in-depth study on the current state of the global Hydraulic Clutch industry with a focus on the Chinese market. The report provides key statistics on the market status of the Hydraulic Clutch manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2011-2016 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Hydraulic Clutch industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2016-2021 market development trends of Hydraulic Clutch industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Hydraulic Clutch Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Hydraulic Clutch industry covering all important parameters.

The Global SAN Switches Market 2016 - Industry Research Report is a professional and in-depth study on the current state of the SAN switches industry. In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Report forecast the global light rail market to grow at a CAGR of 4.76% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global light rail market for the period 2016-2020. To calculate the market size, this report covers revenue generated by the vendors in the market.

The report covers the present scenario and the growth prospects of the global malt ingredients market for the period 2016-2020. To calculate the market size, the report considers the revenue generated through retail sales of malt ingredients in terms of various applications such the alcoholic beverage sector, non-alcoholic beverage sector, food sector, and pharmaceutical and animal feed sectors.

The report covers the present scenario and the growth prospects of the global massage oil market for 2016-2020. The market size was calculated from the revenue generated by the sales of various massage oils used for many purposes, including medical and recreation.

Recently, Neopianroyalty.com discovers the rarest Neopian items players are longing for. These items are so rare, users would need a bountiful amount of cash and Neopoints to the extent that they will buy neopoints cheap just to get their hands on these rare items. These items are considered to be rare because most of these items are only one in existence.

Report forecast the logistics market in Europe to grow at a CAGR of 6.81% during the period 2016-2020. The report covers the present scenario and the growth prospects of the logistics market in Europe for the period 2016-2020. To calculate the market size, the report takes into account the revenue generated by the vendors providing transportation, warehousing, and other VAS as part of outsourced services.